title: Long-term results of combined modality therapy in primary bone lymphomas.
abstract: OBJECTIVE
  To report the Massachusetts General Hospital experience in the management of patients with primary bone lymphoma (PBL) treated with combined modality therapy (CMT).
  
  
  METHODS
  Records from 37 eligible patients were reviewed. Two patients were treated with complete resection of the tumor, while 35 patients underwent radiation therapy with a median total dose of 54 Gy (range 38.35-66.5). All patients received combination chemotherapy, which contained doxorubicin in 33 cases. We compared the current data with our previous experience in patients treated with local measures only.
  
  
  RESULTS
  Actuarial disease-free survival (DFS) at 5 and 10 years is 78% and 73%, respectively, while overall survival (OS) is 91% and 87%, respectively. No local failures were seen. Pathologic fracture at presentation influenced DFS (p = 0.005) and OS (p = 0.017) adversely. OS was compromised in patients older than 60 years (p = 0.059) and DFS in patients with pelvic primaries (p = 0.015). CMT was associated with improved DFS (p = 0.0008) and OS p = 0.0001) compared to our historical controls. Ten patients (27%) developed complications requiring orthopedic procedures following completion of therapy at a median of 25.5 months (range 4-228).
  
  
  CONCLUSIONS
  Patients with PBL have a favorable outcome with CMT, which appears superior to radiation therapy alone. Late complications can be seen, especially in weight-bearing bones.
authors.affiliation: Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. PFidias2@Partners.org
authors.forename: P
authors.initials: P
authors.lastname: Fidias
authors.forename: I
authors.initials: I
authors.lastname: Spiro
authors.forename: M L
authors.initials: ML
authors.lastname: Sobczak
authors.forename: G P
authors.initials: GP
authors.lastname: Nielsen
authors.forename: E F
authors.initials: EF
authors.lastname: Ruffolo
authors.forename: H
authors.initials: H
authors.lastname: Mankin
authors.forename: H D
authors.initials: HD
authors.lastname: Suit
authors.forename: D C
authors.initials: DC
authors.lastname: Harmon
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000628:therapy*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019637:Orthopedic Procedures; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents